| 期刊簡介 | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Acta Endocrinologica-Bucharest LetPub Score 4.8
50 ratings
Rate
Reputation 5.6 Influence 3.4 Speed 9.1 | ||||||||||||||||||||||||
| 期刊簡稱 | ACTA ENDOCRINOL-BUCH | ||||||||||||||||||||||||
| ISSN | 1841-0987 | ||||||||||||||||||||||||
| E-ISSN | 1843-066X | ||||||||||||||||||||||||
| h-index | 10 | ||||||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||||||
| 自引率 (2023-2024) | 14.30%自引率趨勢 | ||||||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||||||
| 官方網站 | http://www.acta-endo.ro/ | ||||||||||||||||||||||||
| 在線稿件提交 | https://mc.manuscriptcentral.com/aeb | ||||||||||||||||||||||||
| 開放訪問 | Yes | ||||||||||||||||||||||||
| 出版商 | Acta Endocrinologica Foundation | ||||||||||||||||||||||||
| 主題領域 | 医学 | ||||||||||||||||||||||||
| 出版國/地區 | ROMANIA | ||||||||||||||||||||||||
| 發行頻率 | 四半期刊行 | ||||||||||||||||||||||||
| 創刊年 | 2005 | ||||||||||||||||||||||||
| 每年文章數 | 39每年文章數趨勢 | ||||||||||||||||||||||||
| 黃金OA百分比 | 0.00% | ||||||||||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q4
| ||||||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1841-0987%5BISSN%5D | ||||||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Slow, 6-12 Week(s) | ||||||||||||||||||||||||
| 競爭力 * | 來自作者的數據: Easy | ||||||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||||||
|
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [Acta Endocrinologica-Bucharest] 的評論 | 撰寫評論 |
| 作者: 芙蓉承颜 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-04-12 10:33:00 評論於 I've been scammed. It's been almost 4 months since I submitted my manuscript and it's still in the "Awaiting Reviewer Selection" status  (0) 讚！ | 芙蓉承颜  |
| 作者: 芙蓉承颜 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-03-07 16:16:33 評論於 Has anyone submitted an article to this magazine and been accepted before? I have been in the "Awaiting AE Assignment" status for over two months (0) 讚！ | 芙蓉承颜 |
| 作者: 芙蓉承颜 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-02-17 14:31:16 評論於 Have you received the same question, and finally accepted it? (0) 讚！ | 芙蓉承颜 |
| 作者: 素花酱大魔王 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-04-09 13:07:17 評論於 Did you receive it at last? (0) 讚！ | 素花酱大魔王 |
| 作者: 罗汉丹红 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2020-08-27 16:45:06 評論於 The review should be an invitation from the magazine to the author, and does not accept self-submission (0) 讚！ | 罗汉丹红 |
| 作者: 龟甲曼霜 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2018-11-02 17:01:59 評論於 How long does it generally take from receiving to publication? (0) 讚！ | 龟甲曼霜 |
| 作者: 矢泽素玲 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2018-09-27 15:36:07 評論於 The self-citation rate feels too risky, so I'm planning to withdraw the submission (0) 讚！ | 矢泽素玲 |
| 作者: Susan 領域: 医学 審稿時間: 3.0 month(s) 結果: 待定＆不明 撰寫評論 |
2018-09-27 11:09:20 評論於 This self-introduction rate feels too dangerous and I plan to withdraw it. (0) 讚！ | Susan |
| 作者: 西风又蓝 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-07-25 17:32:51 評論於 Super slow... Submitted in February this year, it took about a month to reach "Awaiting EIC decision", and it's still in this status now (0) 讚！ | 西风又蓝 |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-07-14 23:39:47 評論於 As long as we can keep the SCI source journals, it's fine. If the school adopts CiteScore for calculation in the future, there will be nothing to worry about. On the one hand, CiteScore refers to a wider range of journals, and this journal is definitely included. In addition, it is beneficial for smaller journals, reducing the disparity between large and small journals. I hope the school will adopt CiteScore (0) 讚！ | 凌霄高洁 |
| 作者: Baron Stone 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2016-09-06 09:44:30 評論於 Anonymous 2011-06-29 post: SCI(2010): 0.052 (0) 讚！ | Baron Stone |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
